Emalex

Emalex Biosciences

This biopharmaceutical company develops ecopipam, a dopamine receptor antagonist designed to treat pediatric Tourette syndrome and childhood-onset fluency disorders for medical patients.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

IAMA Therapeutics

This company develops small molecule drugs to treat neurodevelopmental and central nervous system disorders for patients with autism and epilepsy.

Engrail

This clinical-stage pharmaceutical company develops targeted small-molecule medicines for patients with neuropsychiatric and neurodevelopmental disorders.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Addex Therapeutics

This biopharmaceutical company develops oral small molecule allosteric modulators for patients with neurological disorders, including addiction, Parkinson's disease, and chronic cough.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.